Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 7 (2010), Issue 12 (December)

1. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
   JAMA, 304(21): 2373-80. [Abstract] [Full-text]
2. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
   JAMA, 304(21): 2373-80. [Abstract] [Full-text]
3. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
   J Natl Cancer Inst, 102(23): 1760-70. [Abstract] [Full-text]
4. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.
   J Natl Cancer Inst, 102(23): 1780-93. [Abstract] [Full-text]
5. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
   Am J Clin Oncol, 33(6): 619-23. [Abstract] [Full-text]
6. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
   Am J Clin Oncol, 33(6): 609-13. [Abstract] [Full-text]
7. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells.
   Nat Cell Biol, 12(12): 1194-204. [Abstract] [Full-text]
8. Metabolic alterations and targeted therapies in prostate cancer.
   J Pathol, 223(2): 283-94. [Abstract] [Full-text]
9. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer.
   J Pathol, 223(1): 81-7. [Abstract] [Full-text]
10. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy.
    Urology, 76(6): 1434-9. [Abstract] [Full-text]
11. Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
    Urology, 76(6): 1519.e8-13. [Abstract] [Full-text]
12. Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer.
    Urology, 76(6): 1409-13. [Abstract] [Full-text]
13. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies.
    Urology, 76(6): 1506-11. [Abstract] [Full-text]
14. Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence.
    Urology, 76(6): 1451-5. [Abstract] [Full-text]
15. Radical cystectomy in patients previously treated for localized prostate cancer.
    Urology, 76(6): 1430-3. [Abstract] [Full-text]
16. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells.
    Gene, 471(1): 1-12. [Abstract] [Full-text]
17. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells.
    Gene, 471(1): 1-12. [Abstract] [Full-text]
18. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.
    Am J Hum Genet, 87(6): 802-12. [Abstract] [Full-text]
19. Endoglin suppresses human prostate cancer metastasis.
    Clin Exp Metastasis, 28(1): 39-53. [Abstract] [Full-text]
20. Endoglin suppresses human prostate cancer metastasis.
    Clin Exp Metastasis, 28(1): 39-53. [Abstract] [Full-text]
21. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
22. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
23. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
24. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
25. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
26. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
27. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
28. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
29. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
30. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
31. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
32. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
33. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
34. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
35. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
36. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
37. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
38. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
39. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
40. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
41. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat.
    Int J Radiat Oncol Biol Phys, 79(1): 239-46. [Abstract] [Full-text]
42. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
43. Electromagnetic-guided dynamic multileaf collimator tracking enables motion management for intensity-modulated arc therapy.
    Int J Radiat Oncol Biol Phys, 79(1): 312-20. [Abstract] [Full-text]
44. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
    Int J Radiat Oncol Biol Phys, 79(1): 195-201. [Abstract] [Full-text]
45. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Int J Radiat Oncol Biol Phys, 79(1): 179-87. [Abstract] [Full-text]
46. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
47. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
48. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
49. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
50. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
51. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
52. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
53. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
54. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
55. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
56. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat.
    Int J Radiat Oncol Biol Phys, 79(1): 239-46. [Abstract] [Full-text]
57. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
58. Electromagnetic-guided dynamic multileaf collimator tracking enables motion management for intensity-modulated arc therapy.
    Int J Radiat Oncol Biol Phys, 79(1): 312-20. [Abstract] [Full-text]
59. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
    Int J Radiat Oncol Biol Phys, 79(1): 195-201. [Abstract] [Full-text]
60. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Int J Radiat Oncol Biol Phys, 79(1): 179-87. [Abstract] [Full-text]
61. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
62. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
    Cancer Genet Cytogenet, 203(2): 230-7. [Abstract] [Full-text]
63. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.
    Cancer Res, 70(24): 10182-91. [Abstract] [Full-text]
64. Reduction in physician reimbursement and use of hormone therapy in prostate cancer.
    J Natl Cancer Inst, 102(24): 1826-34. [Abstract] [Full-text]
65. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Cancer Sci, 102(1): 51-6. [Abstract] [Full-text]
66. XMRV: a new virus in prostate cancer?
    Cancer Res, 70(24): 10028-33. [Abstract] [Full-text]
67. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility.
    Cancer Sci, 102(1): 245-52. [Abstract] [Full-text]
68. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Cancer Sci, 102(1): 51-6. [Abstract] [Full-text]
69. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility.
    Cancer Sci, 102(1): 245-52. [Abstract] [Full-text]
70. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
71. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
72. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
73. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
74. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
75. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
76. Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer.
    J Med Internet Res, 12(4): e67. [Abstract] [Full-text]
77. Thrombin expression in prostate: a novel finding.
    Cancer Invest, 29(1): 62-7. [Abstract] [Full-text]
78. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.
    Med Care, 49(1): 59-66. [Abstract] [Full-text]
79. Thrombin expression in prostate: a novel finding.
    Cancer Invest, 29(1): 62-7. [Abstract] [Full-text]
80. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.
    Med Care, 49(1): 59-66. [Abstract] [Full-text]
81. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
    Br J Radiol, 84(997): 31-7. [Abstract] [Full-text]
82. Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy.
    Acta Oncol, 50(1): 25-34. [Abstract] [Full-text]
83. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
    Acta Oncol, 50(1): 127-33. [Abstract] [Full-text]
84. Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map.
    AJR Am J Roentgenol, 196(1): 123-9. [Abstract] [Full-text]
85. Initial treatment costs of organ-confined prostate cancer: a general perspective.
    BJU Int, 107(1): 1-3. [Abstract] [Full-text]
86. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    BJU Int, 107(1): 28-39. [Abstract] [Full-text]
87. Trifecta outcomes after robot-assisted laparoscopic radical prostatectomy.
    BJU Int, 107(1): 100-4. [Abstract] [Full-text]
88. Documenting the location of prostate biopsies with image fusion.
    BJU Int, 107(1): 53-7. [Abstract] [Full-text]
89. Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979-2006.
    BJU Int, 107(1): 40-5. [Abstract] [Full-text]
90. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.
    BJU Int, 107(1): 126-34. [Abstract] [Full-text]
91. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
    Prostate, 71(2): 168-83. [Abstract] [Full-text]
92. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
    Prostate, 71(2): 125-33. [Abstract] [Full-text]
93. Meta-analysis of genome-wide and replication association studies on prostate cancer.
    Prostate, 71(2): 209-24. [Abstract] [Full-text]
94. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
    Prostate, 71(2): 184-96. [Abstract] [Full-text]
95. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
    Prostate, 71(2): 157-67. [Abstract] [Full-text]
96. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
    Prostate, 71(2): 111-24. [Abstract] [Full-text]
97. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
    Prostate, 71(2): 134-46. [Abstract] [Full-text]
98. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
99. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
    Prostate, 71(2): 168-83. [Abstract] [Full-text]
100. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
     Prostate, 71(2): 125-33. [Abstract] [Full-text]
101. Meta-analysis of genome-wide and replication association studies on prostate cancer.
     Prostate, 71(2): 209-24. [Abstract] [Full-text]
102. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
     Prostate, 71(2): 184-96. [Abstract] [Full-text]
103. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
     Prostate, 71(2): 157-67. [Abstract] [Full-text]
104. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
     Prostate, 71(2): 111-24. [Abstract] [Full-text]
105. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
     Prostate, 71(2): 134-46. [Abstract] [Full-text]
106. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
     Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
107. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
     Prostate, 71(2): 168-83. [Abstract] [Full-text]
108. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
     Prostate, 71(2): 125-33. [Abstract] [Full-text]
109. Meta-analysis of genome-wide and replication association studies on prostate cancer.
     Prostate, 71(2): 209-24. [Abstract] [Full-text]
110. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
     Prostate, 71(2): 184-96. [Abstract] [Full-text]
111. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
     Prostate, 71(2): 157-67. [Abstract] [Full-text]
112. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
     Prostate, 71(2): 111-24. [Abstract] [Full-text]
113. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
     Prostate, 71(2): 134-46. [Abstract] [Full-text]
114. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
     Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
115. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor.
     Cell Signal, 23(3): 507-15. [Abstract] [Full-text]
116. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro.
     Carcinogenesis, 32(1): 93-101. [Abstract] [Full-text]
117. DNA damage phenotype and prostate cancer risk.
     Mutat Res, 719(1): 41-6. [Abstract] [Full-text]
118. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
     J Nucl Med, 52(1): 81-9. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.